(Press-News.org) A study conducted at Vanderbilt University Medical Center and 11 other hospitals and practices across the United States shows that use of low-dose atropine eyedrops, commonly used in a higher dose to treat lazy eye, was no better than a placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years.
The first randomized controlled trial of its kind aimed at identifying an effective way to manage myopia was published last week in JAMA Ophthalmology. It was conducted by the Pediatric Eye Disease Investigator Group and funded by the National Eye Institute (NEI).
“We found, interestingly, and honestly shockingly, that there was no difference in the use of 0.01% atropine and placebo in treating these children who ranged in age from 5 to 12,” said Lori Ann Kehler, OD, associate professor of Ophthalmology and Visual Sciences, chief of the Optometry Service and the Vanderbilt site principal investigator for the study. Of the 187 trial participants, 21 were from VUMC, she said.
The onset of myopia usually occurs between the ages of 7 and 16 when developing eyes can start growing too long axially (from front to back). Instead of focusing images on the retina – the light-sensitive tissue in the back of the eye – images of distant objects are focused at a point in front of the retina which causes people to have poor distance vision while their near vision remains unchanged.
The condition results in the need for eyeglasses to improve distance vision, and it can also result in medical complications and serious uncorrectable vision loss later in life, like retinal detachments or myopic macular degeneration.
The study contradicts earlier studies from East Asia that showed the small dose of atropine is effective in slowing progression of myopia.
In 2017 the Academy of Ophthalmology endorsed the findings from East Asia saying that although the FDA had not approved atropine for this use, there was sufficient evidence for prescribing the low dose for myopia. Ophthalmologists across the country, including at VUMC, began to offer the prescription to young patients with myopia.
“That was a really exciting finding at the time because we had had no treatment options for many years,” Kehler said. The prescription of atropine for treating myopia is not covered by most insurance plans.
“The incidence of myopia is increasing worldwide,” Kehler said. “By 2030 it’s predicted that 39 million people in the U.S. will have myopia. By 2050 that number is expected to increase to more than 44 million people in the U.S. and to 50% of the global population. Once it’s detected in children, it tends to get worse every year,” she said. “Investigators all over the world have tried strategies to intervene, to either stop or slow the worsening of myopia.”
Kehler said it is not known why the incidence of myopia is increasing. “There are several theories. Some believe it’s the increase in the use of screens and screen time, but myopia was increasing even before screens were part of children’s lives. Others think it has to do with industrialization. We were an agricultural society. We were outside more. We weren’t reading. We weren’t looking up close all day. Really, the prevailing thought is whether we’re at a screen or looking at a math book or reading most of the day, we think the lack of sunlight and sustained near effort is what’s causing the increase of myopia.”
Kehler said the percentage of children with myopia using the atropine drop at VUMC is low and estimates fewer than 5% of children with myopia are using the drops nationally.
Going forward, eye specialists should have a frank discussion with parents of children with myopia about the conflicting data between the Asian studies and the new U.S. study.
“The absence of a treatment benefit in our U.S.-based study, compared to East Asian studies, may reflect racial differences in atropine response. The study enrolled fewer Asian children, whose myopia progresses more quickly, and included Black children, whose myopia progresses less quickly compared with other races,” noted the study’s lead co-author, Michael X. Repka, MD, professor of Ophthalmology at Johns Hopkins University, in a news release from the NEI.
“All the studies have shown the drops are safe, so we aren’t putting children at risk if we continue to prescribe the 0.01%,” Kehler said. “But we are telling them there is a difference in these studies and it might have to do with your genetics; it might be that it’s more effective in children from Asia than in the U.S. population,” she said.
Further study is needed, Kehler said. The next step is likely to study a higher dose of atropine to see if children in the U.S. experience a benefit.
A study out of Hong Kong – the LAMP study – found that 0.05% might be more effective.
Kehler said other groups are studying the use of red-light therapy to slow the progression of myopia, and there are also new eyeglass lenses that have been developed to slow the progression of myopia, but they are not yet available in the U.S.
“It’s much harder to get drops in very young children,” Kehler said. “But if we had a spectacle option, that would open the door to treating our younger patients.”
Myopia usually stabilizes in about half of children around 16 years of age and among an increasingly larger percentage as they get older. By their early 20s, about 10% of individuals with myopia will continue to grow more nearsighted, and by age 24 that percentage is 4%.
END
BINGHAMTON, N.Y. -- A proposed machine learning framework and expanded use of blockchain technology could help counter the spread of fake news by allowing content creators to focus on areas where the misinformation is likely to do the most public harm, according to new research from Binghamton University, State University of New York.
The research led by Thi Tran, assistant professor of management information systems at Binghamton University’s School of Management, expands on existing studies by offering tools for recognizing patterns in misinformation and helping ...
BOSTON – Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, officially opened the Legorreta Center for Clinical Transplant Tolerance, the first-of-its kind center in the world dedicated to preventing organ rejection after transplant surgery without the use of lifelong immunosuppressive medications. Immunosuppressive medications prevent the immune system from rejecting a transplanted organ, but come with serious side effects, increasing the chance of infections and other illnesses like cancer, diabetes, and heart disease. The mission of the Legorreta Center is to eliminate these risks by eliminating ...
Abstract
Research investigating social media use typically focus on late adolescents and young adults, despite a growing number of early adolescents, 93% to 97%—having at least one social media platform. Also, early adolescents are more likely to engage with newer sites, such as Snapchat and Instagram, than older platforms such as Facebook and Twitter. Given the evolving landscape of social media, the present study examines the impact of the use of various social media platforms, along with its moderating effects, on adolescents’ academic achievement, using a sample of N = 1,459 early adolescents. Results were such that, as frequency ...
AURORA, Colo. (July 31, 2023) – Researchers at the University of Colorado Anschutz Medical Campus have officially identified a central conduit to obesity: fructose.
While fructose’s contribution to obesity is well-known, a study published today in Philosophical Transactions aggregates a large amount of work to make a full argument for how fructose drives obesity and diseases such as diabetes and fatty liver disease.
“This is an in-depth review on a hypothesis that puts nature at the center of weight ...
In 2016, recognizing that lack of research in female animals was hampering the success of treatments for mood disorders, the National Institutes of Health (NIH) changed its policy for basic research to include sex as a biological variable for basic research, a move that triggered an explosion of research into sex differences.
“Building a strong unbiased foundation of literature will help uncover more effective and sex-specific biomarkers for depression onset and target better treatment,” said Georgia Hodes, assistant professor in the School of Neuroscience, part of the Virginia Tech College of Science.
Hodes and co-author Dawson Kropp, a Ph.D. ...
Carbon dioxide levels in Earth’s atmosphere — and, consequently, ocean temperatures — are rising. How high and how fast ocean temperatures can rise can be learned from temperature measurements of ancient oceans. At the same time, energy exploration also relies on knowing the thermal history of oil and gas source rocks, which is often difficult to determine.
One of the most promising techniques for measuring ancient ocean temperatures and basin thermal histories relies on the co-enrichment of rare heavy oxygen and heavy carbon ...
Losing the ability to see clearly, and losing the ability to think or remember clearly, are two of the most dreaded, and preventable, health issues associated with getting older.
Now, a new study lends further weight to the idea that vision problems and dementia are linked.
In a sample of nearly 3,000 older adults who took vision tests and cognitive tests during home visits, the risk of dementia was much higher among those with eyesight problems – including those who weren’t able ...
August 1, 2023, Mountain View, CA – The SETI Institute is proud to announce that Dr. John Rummel will receive the prestigious 2023 Drake Award, recognizing his extraordinary and innovative programmatic contributions and unwavering advocacy for SETI and astrobiology. Rummel’s illustrious career has included roles at NASA Headquarters, where he served as Senior Scientist for Astrobiology, Planetary Protection Officer, Deputy Chief of the Mission from Planet Earth Study Office, and Program Scientist for SETI/High Resolution Microwave Survey. Despite sometimes facing significant opposition, Rummel has been an unwavering supporter of SETI science and funding, working to ...
Chestnut Hill, Mass. (08/01/2023 - Boston College Assistant Professor of Biology Emrah Altindis has received a two-year, $275,000-grant from the Beatson Foundation to explore the role of gut microbes and viruses triggering the autoimmunity of Type 1 diabetes.
“Our lab is extremely grateful for the generous funding bestowed upon us by the Beatson Foundation,” Altindis said. “The receipt of this grant has evoked a profound sense of both excitement and gratitude within our team. We recognize the significant impact this funding will have on our research endeavors, particularly in the field of Type 1 Diabetes.”
Funding for the project, titled ...
UNIVERSITY PARK, Pa. — A patch of ocean in the North Atlantic is stubbornly cooling while much of the planet warms. This anomaly — dubbed the "cold blob" — has been linked to changes in ocean circulation, but a new study found changes in large-scale atmospheric patterns may play an equally important role, according to an international research team led by Penn State.
“People often think the atmosphere has a very short memory, but here we provide evidence that atmospheric circulation change is significant enough to induce some long-term impact on the climate system,” ...
